The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
Following a robust performance in 2023, Genmab A/Sis strategically expanding its pipeline, enhancing both commercial and developmental capacities, and fostering collaborations. In this growth phase, CEO Jan van de Winkel remains steadfast in applying the pragmatic mindset that has guided the company since its inception in 1999.
“I hope that we will even get better in the future by being super-rational and data-driven,” he said. “This approach...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
